In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...
MIAMI, FLORIDA (EMBARGOED UNTIL MAY 25, 2023, AT 5 P.M. ET) – An early-phase study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...
New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support ...
BRAF is the most commonly mutated gene associated with melanoma, found in more than 50 percent of patients. The gene encodes a cytoplasmic kinase that is a member of the MAPK signal-transduction ...
New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results